



Buy

PT Bank Mandiri (Persero) Tbk

(BMRI.JK / BMRI.IJ)

Price (April 29th, 25)	4940
Target Price	6325
Potential Upside	29%
Market Cap	449.98 T
Number of Share	92.39 B
52w Lo/Hi	4410 / 6025

Source : IDX | Phintraco Sekuritas Research
| as of Apr 29th, 2025

IHSG vs BMRI



Source : IDX

Shareholder	%
PT Biro Klasifikasi	52.00
Public <5%	39.94
Indonesia Investment	8.00
Damawan Junaidi	0.02
Riduan	0.02
Timothy Utama	0.01
Tony Eko Boy Subari	0.01

Source : Company | as of fin. statement 3M25

Wholesale business supports loan growth resilience

Laba bersih BMRI pada FY24 tumbuh 3.9% YoY menjadi Rp13.2 triliun pada 3M25. Pertumbuhan ini sejalan dengan pertumbuhan *Interest Income* yang tumbuh 11.5% YoY, meskipun *Interest Expense* meningkat lebih tinggi (+24.4% YoY) pada 3M25. Sehingga, *Net Interest Margin* (NIM) menjadi sebesar 4.8% (-27 bps YoY) di 3M25 masih lebih rendah dari target BMRI. Untuk FY25F BMRI menargetkan NIM sebesar (5.0%-5.2%) sedikit lebih rendah dari target FY24 yang sebesar (5.0%-5.3%).

Wholesale Business mampu menjaga pertumbuhan kredit BMRI. BMRI mencatatkan pertumbuhan kredit 16.5% YoY menjadi Rp1,672 triliun di 3M25, dengan kontribusi terbesar dari *corporate loan* dan *commercial loan* yang masing-masing tumbuh 37.8% dan 23.5% terhadap total pendapatan. Disisi lain, *Non Performing Loan* meningkat 5 bps QoQ menjadi 1.17% di 3M25. Dari sisi likuiditas, *Loan to Deposit Ratio* (LDR) tercatat lebih tinggi, yaitu 92.5% dibandingkan 88.2% di 3M25. Namun, LDR tersebut telah mendekati batas aman BI (78%-92%).

Kami memperkirakan *Interest Income* BMRI dapat tumbuh 7% YoY pada FY25F. Beberapa faktor seperti membaiknya konsumsi domestik, realisasi investasi swasta maupun Pemerintah, dan hilirisasi berpotensi menopang pertumbuhan kredit BMRI. Posisi BMRI yang kuat di segmen *wholesale* memungkinkan BMRI memanfaatkan peluang pertumbuhan kredit. Optimalisasi pendapatan lain berasal dari *non interest income* (NII) yang salah satunya berasal dari adaptasi Livin', yang kontribusinya meningkat 19.8% YoY terhadap pertumbuhan NII BMRI di 3M25. Sehingga kami memproyeksikan *Interest income* BMRI dapat tumbuh 7% YoY dengan laba bersih dapat tumbuh sekitar 2% YoY di FY25F.

Sehingga, kami mempertahankan *rating Buy* untuk BMRI proyeksi dan nilai wajar yang sama pada *company update* BMRI sebelumnya, yaitu 6325.

PT Bank Mandiri (Persero) Tbk

(in Billion IDR)	1Q24	1Q25	YoY	4Q24	1Q25	QoQ	Phintas Estimate	%Run Rate
Financial Statement								
Interest Income	35,535	39,626	11.5%	40,600	39,626	-2.4%	144,416	27%
Interest Expense	(11,349)	(14,121)	24.4%	(13,446)	(14,121)	5.0%	(55,638)	25%
Net Interest Income	24,186	25,505	5.5%	27,154	25,505	-6.1%	88,778	29%
Net Income	12,702	13,197	3.9%	13,766	13,197	-4.1%	56,936	23%
Financial Ratio								
NIM	5.1%	4.8%	-0.3%					
ROE	19.7%	18.9%	-0.8%					
CASA Ratio	74.4%	72.6%	-1.8%					
Loan Growth	20.1%	17.0%	-3.1%					
NPL	1.2%	1.2%	0.0%					
LDR	88.2%	92.5%	4.3%					
CAR	19.9%	18.5%	-1.4%					

Source : Company | Phintraco Sekuritas Research




PHINTRACO SEKURITAS

Rating for Stocks :

- Buy : The stock is expected to give total return (price appreciation + dividend yield) of > +10% over the next 12 months.
- Hold : The stock is expected to give total return of > 0% to \leq +10% over the next 12 months.
- Sell : The stock is expected to give total return of < 0% over the next 12 months.
- Outperform : The stock is expected to do slightly better than the market return. Equal to "moderate buy"
- Underperform : The stock is expected to do slightly worse than the market return. Equal to "moderate sell"

PHINTRACO SEKURITAS
Kantor Cabang & Mitra GI BEI



DISCLAIMER: The information on this document is provided for information purpose only, It does not constitute any offer, recommendation or solicitation to any person to enter into any transaction or adopt any trading or investment strategy, nor does it constitute any prediction of likely future movement in prices, Users of this document should seek advice regarding the appropriateness of investing in any securities, financial instruments or investment strategies referred to on this document and should understand that statements regarding future prospects may not be realized, Opinion, Projections and estimates are subject to change without notice, Phintraco Sekuritas is not an investment adviser, and is not purporting to provide you with investment advice, Phintraco Sekuritas accepts no liability whatsoever for any direct or consequential loss arising from the use of this report or its contents, This report may not be reproduced, distributed or published by any recipient for any purpose.